ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Image-guided brachytherapy in patients with inoperable FIGO 2009 stage IVB endometrial cancer who were not candidates for palliative surgery.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn patients with endometrial cancer (EC) with metastases at diagnosis, palliative treatment is the only therapy considered and to our knowledge there is no literature on the evolution of these patients following external-beam-irradiation (EBRT) and image-guided brachytherapy (IGBT). We present the clinical outcomes of 11 FIGO 2009 stage-IVB EC patients treated with IGBT ± EBRT. METHODS/PATIENTS: From July 2009 to February 2018, 11 stage IVB patients were treated with IGBT ± EBRT in 4 European centres. The treatments and the outcomes of these patients were analysed. STATISTICS: Kaplan-Meier and descriptive analysis were used for analysing overall survival (OS).
resultsThe median age was 63 years (46-79) and the median follow-up was 39 months (8-128). The sites of metastases were reported in 8/11 patients: the lung in 4 patients, peritoneal and liver metastasis in one, pleural metastasis in one, bone in one and inguinal lymph nodes in one. Seven patients underwent chemotherapy (5 achieving complete response (CR)). Two patients received IGBT alone and 9 EBRT + IGBT. Three developed uterine relapse, 3 lymph node relapse and all died. Four had distant metastases and only one was alive after treatment. The OS was 69.3% at 2 and 3 years and 41.6% at 5 and 10 years.
conclusionIn this series, patients with stage IVB EC with CR after chemotherapy and treated with IGBT ± EBRT achieved an OS of 41.6% at 5 and 10 years. Local treatment with EBRT ± IGBT should be considered mainly in good responders to chemotherapy and should be validated in prospective trials including biological markers.
Indexed as
Identifiers
42251630What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.